PPI + NOAC tick

Pharmacy Daily - - Front Page -

NEW re­search has con­firmed the im­por­tance of ad­min­is­ter­ing pro­ton pump in­hibitors (PPIs) con­comi­tantly with war­farin or non-vi­ta­min K oral an­ti­co­ag­u­lants (NOACs) such as ri­varox­a­ban (Bayer’s Xarelto), dabi­ga­tran (BI’s Pradaxa) and apix­a­ban (Pfizer’s Eliquis).

Re­searchers from the Van­der­bilt Univer­sity School of Medicine in­ves­ti­gated data re­lat­ing to 1,643,123 pa­tients with 1,713,183 new episodes of oral an­ti­co­ag­u­lant treat­ment in­cluded in the co­hort and 1,161,989 per­son-years of fol­low-up.

Past stud­ies have shown apix­a­ban to be as­so­ci­ated with the low­est rate of up­per GI bleed­ing, while ri­varox­a­ban and war­farin had the high­est rates.

This study was said to be con­sis­tent with all pre­vi­ous data around these prod­ucts and au­thors said the in­for­ma­tion should “in­form as­sess­ment of risks and ben­e­fits when choos­ing an­ti­co­ag­u­lant agents”.

See ja­manet­work.com for more.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.